Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 7, 2009, Pages 2-9

  Hawkey, P M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

GISA; Glycopeptide resistance; HGISA; Laboratory testing; Review; Staphylococcus aureus; Visa

Indexed keywords

GENE PRODUCT; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN VANA; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; GENE CLUSTER; GENE IDENTIFICATION; GLYCOPEPTIDE INTERMEDIATE STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 71649105095     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03094.x     Document Type: Review

References (61)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
2. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998, 42:1303-1304.
3. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006, 42(suppl 1):S25-S34.
4. Uttley AH, George RC, Naidoo J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989, 103:173-181.
5. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992, 72:195-198.
6. Chang S, Sievert DM, Hageman JC. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
7. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408.
8. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006, 12(suppl 1):16-23.
9. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006, 6:156.
10. Waldron DE, Lindsay JA. Sau1: a novel lineage-specific type I restriction-modification system that blocks horizontal gene transfer into Staphylococcus aureus and between S. aureus isolates of different lineages. J Bacteriol 2006, 188:5578-5585.
11. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003, 52:864-868.
12. Laboratory detection of vancomycin-intermediate/resistant Staphylococcus aureus (VISA/VRSA) 2006, Atlanta, GA, CDC
13. Tenover FC, Weigel LM, Appelbaum PC. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004, 48:275-280.
14. Hiramatsu K, Aritaka N, Hanaki H. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
15. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
16. Wootton M, Bennett PM, MacGowan AP, Walsh TR. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains. J Antimicrob Chemother 2005, 56:944-947.
17. Performance standards for antimicrobial susceptibility testing 2006, 16th Informational Supplement M100-S/6, Wayne, PA, CLSI
18. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000, 44:2276-2285.
19. Cui L, Ma X, Sato K. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003, 41:5-14.
20. Cui L, Iwamoto A, Lian JQ. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:428-438.
21. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003, 185:7103-7110.
22. Avison MB, Bennett PM, Howe RA, Walsh TR. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. J Antimicrob Chemother 2002, 49:255-260.
23. Wootton M, Walsh TR, MacGowan AP. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:3982-3983.
24. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47:399-403.
25. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 2008, 52:45-53.
26. Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:3404-3413.
27. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 2003, 49:807-821.
28. Gardete S, Wu SW, Gill S, Tomasz A. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:3424-3434.
29. Utaida S, Dunman PM, Macapagal D. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 2003, 149:2719-2732.
30. McAleese F, Wu SW, Sieradzki K. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J Bacteriol 2006, 188:1120-1133.
31. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, Davies JK. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:3755-3762.
32. Herbert S, Bera A, Nerz C. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog 2007, 3:e102.
33. Meehl M, Herbert S, Gotz F, Cheung A. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:2679-2689.
34. Kato Y, Suzuki T, Ida T. Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance. Int J Antimicrob Agents 2008, 31:64-70.
35. Camargo IL, Neoh HM, Cui L, Hiramatsu K. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus with a hetero-VISA phenotype. Antimicrob Agents Chemother 2008, 52:672-679.
36. Mwangi MM, Wu SW, Zhou Y. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007, 104:9451-9456.
37. Sakoulas G, Eliopoulos GM, Moellering RC. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002, 46:1492-1502.
38. Renzoni A, Barras C, Francois P. Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:3048-3061.
39. Howden BP, Smith DJ, Mansell A. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008, 8:39.
40. Goldstein F. The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 2007, 59:1-4.
41. Maor Y, Rahav G, Belausov N, Ben David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007, 45:1511-1514.
42. Vancomycin-resistant Staphylococcus aureus-New York 2004. MMWR 2004, 53:322-323.
43. de Lassence A, Hidri N, Timsit JF. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006, 42:170-178.
44. Wootton M. The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero-VISA detection methods. Int J Antimicrob Agents 2006, 28:586.
45. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998, 351:602.
46. Tenover FC, Lancaster MV, Hill BC. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998, 36:1020-1027.
47. Lulitanond A, Chanawong A, Sribenjalux P. Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks. Southeast Asian J Trop Med Public Health 2006, 37:761-767.
48. Walsh TR, Bolmstrom A, Qwarnstrom A. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39:2439-2444.
49. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45:329-332.
50. Voss A, Mouton JW, van Elzakker EP. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 2007, 6:9.
51. Fitzgibbon MM, Rossney AS, O'Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol 2007, 45:3263-3269.
52. Yusof A, Engelhardt A, Karlsson A. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008, 46:3042-3047.
53. Amiali NM, Mulvey MR, Berger-Bachi B, Sedman J, Simor AE, Ismail AA. Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2008, 61:95-102.
54. Scherl A, Francois P, Charbonnier Y. Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. BMC Genomics 2006, 7:296.
55. Drummelsmith J, Winstall E, Bergeron MG, Poirier GG, Ouellette M. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. J Proteome Res 2007, 6:4690-4702.
56. Stapleton MR, Horsburgh MJ, Hayhurst EJ. Characterization of IsaA and SceD, two putative lytic transglycosylases of Staphylococcus aureus. J Bacteriol 2007, 189:7316-7325.
57. Neoh HM, Hori S, Komatsu M. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007, 6:13.
58. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004, 10:855-857.
59. Nunes AP, Schuenck RP, Bastos CC. Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia. Braz J Infect Dis 2007, 11:345-350.
60. Watanabe Y, Neoh HM, Cui L, Hiramatsu K. Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus (VISA). Antimicrob Agents Chemother 2008, 52:4207-4208.
61. Howe RA, Wootton M, Walsh TR, Bennett PM, MacGowan AP. Heterogeneous resistance to vancomycin in Staphylococcus aureus. J Antimicrob Chemother 2000, 45:130-132.